Schroder Investment Management Group’s BridgeBio Pharma BBIO Stock Holding History

Schroder Investment Management Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.2M	Sell	113,889 -995	-0.9%	-$69.7K	0.01%	708
2026 Q1	$7.97M	Buy	114,884 +52,527	+84%	+$3.81M	0.01%	706
2025 Q4	$4.71M	Hold	62,357	–	–	﹤0.01%	754
2025 Q3	$3.24M	Buy	+62,357	New	+$3.04M	﹤0.01%	845
2025 Q2	–	Sell	-34,741	Closed	-$1.22M	–	1164
2025 Q1	$1.22M	Hold	34,741	–	–	﹤0.01%	965
2024 Q4	$949K	Buy	+34,741	New	+$898K	﹤0.01%	1026
2024 Q2	–	Sell	-58,697	Closed	-$1.81M	–	1202
2024 Q1	$1.81M	Buy	+58,697	New	+$2M	﹤0.01%	933

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Schroder Investment Management Group's BBIO Position: Q2 2026 in Review

Schroder Investment Management Group reduced its BridgeBio Pharma (BBIO) stake by 0.87% in Q2 2026, selling an estimated $69.7K and leaving 113,889 shares worth $8.2M. The position accounts for 0.01% of the portfolio, ranked #708.

Schroder Investment Management Group first reported a position in BBIO in Q1 2024 and has held it in 7 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Schroder Investment Management Group held 113,889 shares of BridgeBio Pharma worth $8.2M as of Q2 2026.
Schroder Investment Management Group sold 995 BridgeBio Pharma shares in Q2 2026, an estimated $69.7K.
BridgeBio Pharma made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #708 holding.
Schroder Investment Management Group first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 7 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.